554 related articles for article (PubMed ID: 14618549)
1. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.
Mori S; Mori E; Iseki E; Kosaka K
Psychiatry Clin Neurosci; 2006 Apr; 60(2):190-5. PubMed ID: 16594943
[TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Leroi I; Brandt J; Reich SG; Lyketsos CG; Grill S; Thompson R; Marsh L
Int J Geriatr Psychiatry; 2004 Jan; 19(1):1-8. PubMed ID: 14716693
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
Ikeda M; Mori E; Kosaka K; Iseki E; Hashimoto M; Matsukawa N; Matsuo K; Nakagawa M;
Dement Geriatr Cogn Disord; 2013; 36(3-4):229-41. PubMed ID: 23949147
[TBL] [Abstract][Full Text] [Related]
7. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
Burn DJ; McKeith IG
Mov Disord; 2003 Sep; 18 Suppl 6():S72-9. PubMed ID: 14502659
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
10. Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
Ishikawa K; Motoi Y; Mizuno Y; Kubo S; Hattori N
Psychogeriatrics; 2014 Jun; 14(2):93-100. PubMed ID: 24661498
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Kaufer DI
Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].
Drach LM
Med Monatsschr Pharm; 2011 Feb; 34(2):47-52; quiz 53-4. PubMed ID: 21428015
[TBL] [Abstract][Full Text] [Related]
16. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.
Aarsland D; Mosimann UP; McKeith IG
J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):164-71. PubMed ID: 15312280
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
18. Delayed blink reflex in dementia with Lewy bodies is sensitive to cholinergic modulation.
Anzellotti F; Bonanni L; Iorio E; Di Baldassarre F; D'Andreagiovanni A; Monaco D; Thomas A; Onofrj M
Clin Neuropharmacol; 2008; 31(4):231-7. PubMed ID: 18670247
[TBL] [Abstract][Full Text] [Related]
19. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
20. The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia.
Imamura K; Wada-Isoe K; Kowa H; Tanabe Y; Nakashima K
Neurocase; 2008; 14(3):271-5. PubMed ID: 18645736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
